The insulin delivery devices market size has grown strongly in recent years. It will grow from $19.07 billion in 2025 to $20.61 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to rising prevalence of diabetes, growing awareness of diabetes management, increased availability of insulin therapies, expansion of healthcare access, rising adoption of self-injection practices.
The insulin delivery devices market size is expected to see strong growth in the next few years. It will grow to $28.03 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing global diabetic population, rising demand for convenient insulin delivery methods, growing focus on long-term diabetes management, expanding access to diabetes care in emerging markets, increasing adoption of home healthcare solutions. Major trends in the forecast period include rising adoption of insulin pens over traditional syringes, growing demand for insulin pumps for continuous insulin delivery, increasing preference for user-friendly and portable insulin devices, expansion of home-based diabetes management solutions, growing use of disposable and pre-filled insulin delivery devices.
The increasing prevalence of diabetes is expected to drive the growth of the insulin delivery device market in the coming years. Diabetes is a chronic condition characterized by elevated blood sugar levels due to either insufficient insulin production by the pancreas or the body’s inability to effectively use insulin. The rise in diabetes cases is largely attributed to factors such as sedentary lifestyles, poor diets, and increasing obesity rates worldwide. Insulin delivery devices are essential for managing diabetes, as they allow individuals to control their blood sugar levels effectively by administering insulin in a controlled and convenient manner, thus preventing complications and promoting overall health. For example, according to the International Diabetes Federation, a Belgium-based non-governmental organization, in 2024, approximately 589 million adults aged 20-79 were living with diabetes worldwide. This figure is projected to rise to 853 million by 2050. This growing prevalence of diabetes is fueling the expansion of the insulin delivery device market.
Leading companies in the insulin delivery device market are focusing on developing innovative products, such as insulin pumps, which provide continuous or customizable insulin delivery. Insulin pumps are programmable medical devices that deliver insulin continuously or on demand through a catheter placed under the skin. For instance, in May 2023, Beta Bionics, a U.S.-based medical technology company, received approval from the U.S. Food and Drug Administration for its iLet ACE Pump and iLet Dosing Decision Software. The iLet Bionic Pancreas system, designed for individuals aged six and older with type 1 diabetes, integrates two devices with a compatible FDA-cleared integrated continuous glucose monitor (iCGM). This system operates using an automated insulin dosing (AID) system driven by an adaptive closed-loop algorithm, which only requires the user’s body weight for setup and eliminates the need for additional insulin dosing parameters. Unlike traditional pump therapy, this system requires no manual adjustment of settings, making it easier to initiate and manage. Additionally, the iLet device introduces a meal announcement feature that simplifies mealtime insulin dosing by categorizing meals as small, medium, or large, with the algorithm learning and adapting to individual insulin needs over time.
In September 2023, Abbott, a U.S.-based healthcare company, acquired Bigfoot Biomedical for an undisclosed amount. This acquisition strengthens Abbott’s position in diabetes care by expanding its renowned FreeStyle Libre portfolio of continuous glucose monitoring technology. The move aligns with Abbott’s strategy to advance connected solutions, aiming to personalize and refine diabetes management. Bigfoot Biomedical is a U.S.-based manufacturer of insulin delivery devices.
Major companies operating in the insulin delivery devices market are Novo Nordisk A/S, Medtronic Plc, Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed Holding AG, Becton Dickinson and Company, Sanofi SA, Eli Lilly and Company, Abbott Laboratories, EOFlow Co. Ltd., Beta Bionics Inc., Bigfoot Biomedical Inc., CeQur Corporation, Emperra GmbH, Debiotech SA, AMF Medical SA, Aerami Therapeutics Inc., Andain Inc., Apex Medical Devices, Animas Corporation.
North America was the largest region in the insulin delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the insulin delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the insulin delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have introduced cost pressures in the insulin delivery devices market by increasing duties on imported medical-grade plastics, electronic components, and precision manufacturing equipment. These impacts have raised production and distribution costs, particularly affecting insulin pumps, smart devices, and pen-based delivery systems, with north america and asia-pacific regions experiencing higher exposure due to globalized supply chains. Healthcare providers and pharmacies have faced pricing pressures that influence device affordability and adoption. On the positive side, tariffs have encouraged local manufacturing, regional sourcing of components, and supply chain diversification, supporting long-term production resilience.
The insulin delivery devices market research report is one of a series of new reports that provides insulin delivery devices market statistics, including insulin delivery devices industry global market size, regional shares, competitors with a insulin delivery devices market share, detailed insulin delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the insulin delivery devices industry. This insulin delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Insulin delivery devices are medical tools designed to administer insulin to individuals with diabetes. These devices are essential for managing blood glucose levels in people who are unable to produce sufficient insulin naturally. They help control blood sugar levels effectively, offering flexibility and convenience in insulin administration.
The primary types of insulin delivery devices include insulin syringes, insulin jet injectors, pen needles, reusable insulin pens, disposable insulin pens, insulin pumps, external or tethered pumps, and patch pumps. Insulin syringes, in particular, are designed for the subcutaneous injection of insulin, featuring fine, short needles and clearly marked dosage indicators to ensure precise hormone delivery. These devices are used for both type 1 and type 2 diabetes and are available through various channels, including hospital pharmacies, retail pharmacies, online sales, and diabetes clinics or centers.
The insulin delivery devices market consists of sales of insulin infusion sets, insulin reservoirs, insulin pump accessories, and insulin cartridges. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The insulin delivery devices market size is expected to see strong growth in the next few years. It will grow to $28.03 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to increasing global diabetic population, rising demand for convenient insulin delivery methods, growing focus on long-term diabetes management, expanding access to diabetes care in emerging markets, increasing adoption of home healthcare solutions. Major trends in the forecast period include rising adoption of insulin pens over traditional syringes, growing demand for insulin pumps for continuous insulin delivery, increasing preference for user-friendly and portable insulin devices, expansion of home-based diabetes management solutions, growing use of disposable and pre-filled insulin delivery devices.
The increasing prevalence of diabetes is expected to drive the growth of the insulin delivery device market in the coming years. Diabetes is a chronic condition characterized by elevated blood sugar levels due to either insufficient insulin production by the pancreas or the body’s inability to effectively use insulin. The rise in diabetes cases is largely attributed to factors such as sedentary lifestyles, poor diets, and increasing obesity rates worldwide. Insulin delivery devices are essential for managing diabetes, as they allow individuals to control their blood sugar levels effectively by administering insulin in a controlled and convenient manner, thus preventing complications and promoting overall health. For example, according to the International Diabetes Federation, a Belgium-based non-governmental organization, in 2024, approximately 589 million adults aged 20-79 were living with diabetes worldwide. This figure is projected to rise to 853 million by 2050. This growing prevalence of diabetes is fueling the expansion of the insulin delivery device market.
Leading companies in the insulin delivery device market are focusing on developing innovative products, such as insulin pumps, which provide continuous or customizable insulin delivery. Insulin pumps are programmable medical devices that deliver insulin continuously or on demand through a catheter placed under the skin. For instance, in May 2023, Beta Bionics, a U.S.-based medical technology company, received approval from the U.S. Food and Drug Administration for its iLet ACE Pump and iLet Dosing Decision Software. The iLet Bionic Pancreas system, designed for individuals aged six and older with type 1 diabetes, integrates two devices with a compatible FDA-cleared integrated continuous glucose monitor (iCGM). This system operates using an automated insulin dosing (AID) system driven by an adaptive closed-loop algorithm, which only requires the user’s body weight for setup and eliminates the need for additional insulin dosing parameters. Unlike traditional pump therapy, this system requires no manual adjustment of settings, making it easier to initiate and manage. Additionally, the iLet device introduces a meal announcement feature that simplifies mealtime insulin dosing by categorizing meals as small, medium, or large, with the algorithm learning and adapting to individual insulin needs over time.
In September 2023, Abbott, a U.S.-based healthcare company, acquired Bigfoot Biomedical for an undisclosed amount. This acquisition strengthens Abbott’s position in diabetes care by expanding its renowned FreeStyle Libre portfolio of continuous glucose monitoring technology. The move aligns with Abbott’s strategy to advance connected solutions, aiming to personalize and refine diabetes management. Bigfoot Biomedical is a U.S.-based manufacturer of insulin delivery devices.
Major companies operating in the insulin delivery devices market are Novo Nordisk A/S, Medtronic Plc, Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed Holding AG, Becton Dickinson and Company, Sanofi SA, Eli Lilly and Company, Abbott Laboratories, EOFlow Co. Ltd., Beta Bionics Inc., Bigfoot Biomedical Inc., CeQur Corporation, Emperra GmbH, Debiotech SA, AMF Medical SA, Aerami Therapeutics Inc., Andain Inc., Apex Medical Devices, Animas Corporation.
North America was the largest region in the insulin delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the insulin delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the insulin delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have introduced cost pressures in the insulin delivery devices market by increasing duties on imported medical-grade plastics, electronic components, and precision manufacturing equipment. These impacts have raised production and distribution costs, particularly affecting insulin pumps, smart devices, and pen-based delivery systems, with north america and asia-pacific regions experiencing higher exposure due to globalized supply chains. Healthcare providers and pharmacies have faced pricing pressures that influence device affordability and adoption. On the positive side, tariffs have encouraged local manufacturing, regional sourcing of components, and supply chain diversification, supporting long-term production resilience.
The insulin delivery devices market research report is one of a series of new reports that provides insulin delivery devices market statistics, including insulin delivery devices industry global market size, regional shares, competitors with a insulin delivery devices market share, detailed insulin delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the insulin delivery devices industry. This insulin delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Insulin delivery devices are medical tools designed to administer insulin to individuals with diabetes. These devices are essential for managing blood glucose levels in people who are unable to produce sufficient insulin naturally. They help control blood sugar levels effectively, offering flexibility and convenience in insulin administration.
The primary types of insulin delivery devices include insulin syringes, insulin jet injectors, pen needles, reusable insulin pens, disposable insulin pens, insulin pumps, external or tethered pumps, and patch pumps. Insulin syringes, in particular, are designed for the subcutaneous injection of insulin, featuring fine, short needles and clearly marked dosage indicators to ensure precise hormone delivery. These devices are used for both type 1 and type 2 diabetes and are available through various channels, including hospital pharmacies, retail pharmacies, online sales, and diabetes clinics or centers.
The insulin delivery devices market consists of sales of insulin infusion sets, insulin reservoirs, insulin pump accessories, and insulin cartridges. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Insulin Delivery Devices Market Characteristics
3. Insulin Delivery Devices Market Supply Chain Analysis
4. Global Insulin Delivery Devices Market Trends and Strategies
5. Insulin Delivery Devices Market Analysis of End Use Industries
7. Global Insulin Delivery Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Insulin Delivery Devices Total Addressable Market (TAM) Analysis for the Market
9. Insulin Delivery Devices Market Segmentation
10. Insulin Delivery Devices Market Regional and Country Analysis
11. Asia-Pacific Insulin Delivery Devices Market
12. China Insulin Delivery Devices Market
13. India Insulin Delivery Devices Market
14. Japan Insulin Delivery Devices Market
15. Australia Insulin Delivery Devices Market
16. Indonesia Insulin Delivery Devices Market
17. South Korea Insulin Delivery Devices Market
18. Taiwan Insulin Delivery Devices Market
19. South East Asia Insulin Delivery Devices Market
20. Western Europe Insulin Delivery Devices Market
21. UK Insulin Delivery Devices Market
22. Germany Insulin Delivery Devices Market
23. France Insulin Delivery Devices Market
24. Italy Insulin Delivery Devices Market
25. Spain Insulin Delivery Devices Market
26. Eastern Europe Insulin Delivery Devices Market
27. Russia Insulin Delivery Devices Market
28. North America Insulin Delivery Devices Market
29. USA Insulin Delivery Devices Market
30. Canada Insulin Delivery Devices Market
31. South America Insulin Delivery Devices Market
32. Brazil Insulin Delivery Devices Market
33. Middle East Insulin Delivery Devices Market
34. Africa Insulin Delivery Devices Market
36. Insulin Delivery Devices Market Competitive Landscape and Company Profiles
37. Insulin Delivery Devices Market Other Major and Innovative Companies
40. Insulin Delivery Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Insulin Delivery Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses insulin delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for insulin delivery devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The insulin delivery devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Insulin Syringes; Insulin Jet Injectors; Pen Needles; Reusable Insulin Pens; Disposable Insulin Pens2) By Disease Indication: Type 1; Type 2
3) By Distribution Channels: Hospital Pharmacies; Retail Pharmacies; Online Sales; Diabetes Clinics Or Centers
Subsegments:
1) By Insulin Syringes: Standard Insulin Syringes; Insulin Syringes With Fixed Or Adjustable Needle Length2) By Insulin Jet Injectors: Needle-Free Insulin Jet Injectors; High-Pressure Insulin Jet Injectors
3) By Pen Needles: Short Pen Needles; Long Pen Needles
4) By Reusable Insulin Pens: Reusable Pens With Replaceable Cartridges; Refillable Insulin Pens
5) By Disposable Insulin Pens: Single-Use Disposable Insulin Pens; Pre-Filled Disposable Insulin Pens
Companies Mentioned: Novo Nordisk A/S; Medtronic Plc; Insulet Corporation; Tandem Diabetes Care Inc.; Ypsomed Holding AG; Becton Dickinson and Company; Sanofi SA; Eli Lilly and Company; Abbott Laboratories; EOFlow Co. Ltd.; Beta Bionics Inc.; Bigfoot Biomedical Inc.; CeQur Corporation; Emperra GmbH; Debiotech SA; AMF Medical SA; Aerami Therapeutics Inc.; Andain Inc.; Apex Medical Devices; Animas Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Insulin Delivery Devices market report include:- Novo Nordisk A/S
- Medtronic Plc
- Insulet Corporation
- Tandem Diabetes Care Inc.
- Ypsomed Holding AG
- Becton Dickinson and Company
- Sanofi SA
- Eli Lilly and Company
- Abbott Laboratories
- EOFlow Co. Ltd.
- Beta Bionics Inc.
- Bigfoot Biomedical Inc.
- CeQur Corporation
- Emperra GmbH
- Debiotech SA
- AMF Medical SA
- Aerami Therapeutics Inc.
- Andain Inc.
- Apex Medical Devices
- Animas Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 20.61 Billion |
| Forecasted Market Value ( USD | $ 28.03 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
